

18 September 2018

Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")

Notice of Interim Results

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), will be announcing its Interim Results for the six months ended 30 June 2018 on Monday 24 September 2018.

Management will be hosting a presentation for analysts on the day of results at 9:45 a.m. at the offices of Arden Partners plc, 125 Old Broad Street, London, EC2N 1AR.

Analysts who wish to attend should register their interest with Heather Armstrong contactable at heather.armstrong@investor-focus.co.uk or 0203 934 6630.

Deltex Medical Group plc

01243 774 837
investorinfo@Deltexmedical.com

Nigel Keen, Chairman
Andy Mears, Chief Executive
Jonathan Shaw, Group Finance Director

Nominated Adviser & Broker
Arden Partners plc

020 7614 5900

Chris Hardie
Ciaran Walsh

Joint Broker
Turner Pope Investments (TPI) Ltd

0203 621 4120
info@turnerpope.com

Andy Thacker

Financial Public Relations
IFC Advisory Ltd

0203 934 6630

Tim Metcalfe
Graham Herring
Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary oesophageal doppler monitoring ("ODM") (TrueVue Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in flow and measures such changes in 'real time'. Deltex Medical has been the only group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology,

TrueVue Doppler, which has been demonstrated to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Group goal

Haemodynamic management is now becoming widely accepted as an important part of the anaesthesia protocol for high risk surgical patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA - and through distribution arrangements in approximately 40 other countries.